Objective: Our aim was to determine whether chronic CGP treatment mitigates contractile dysfunction and arrhythmias in an animal model of heart failure (HF) and sudden cardiac death (SCD).
T he clinical syndrome of heart failure (HF), which can occur after acute myocardial ischemic injury or after longstanding chronic cardiovascular disease, is a progressive disease often involving a phase of compensatory hypertrophy followed by a transition to impaired contractility (decompensation) with systolic or diastolic dysfunction. Although mortality in the later stages of the disease is most often attributed to impaired pump function, sudden cardiac death (SCD) is the leading cause of mortality in patients with mild to moderate HF, accounting for 35 to 50% of deaths, 1, 2 prompting an increase in the use of implantable cardiac defibrillators as prophylactic devices. 3 The mechanisms underlying SCD, and the transition from compensated to decompensated HF, are incompletely understood, but neurohormonal abnormalities, ion channel/ transporter changes, Ca 2+ handling alterations, the activation of intra-and extracellular signaling pathways, and oxidative stress have all been implicated in the pathophysiology. 4 
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A limitation of energy production or substrate utilization is also thought to contribute to HF, [5] [6] [7] and several studies have reported HF-associated defects in mitochondrial function. [8] [9] [10] Mitochondria are not only the predominant source of ATP, on which normal cardiac function depends, but also play a critical role in other biological processes such as redox regulation, intermediary metabolism, cell signaling, and ion homeostasis. In the context of HF, the most detrimental consequences of mitochondrial dysfunction, either as the primary or as a secondary factor in the development of HF, are impaired bioenergetics and increased oxidative stress. Reactive oxygen species (ROS) have complex effects on the development of HF, playing a key role in cardiac remodeling by activating multiple signaling pathways involved in hypertrophic growth of cardiomyocytes, apoptosis, and proliferation of fibroblasts. 11 Increased oxidative stress also impairs cardiac function directly by modifying the proteins involved in excitationcontraction coupling. 12, 13 Targeting mitochondria to improve bioenergetics and to maintain redox balance is emerging as a novel therapeutic strategy for HF. [14] [15] [16] Upstream of oxidative stress, recent evidence has suggested that altered Na + and Ca 2+ gradients across the mitochondrial inner membrane may be a proximal factor in the imbalance of energy supply and demand, 17, 18 as well as ROS balance, 19 in failing heart cells. The pathway of contractile and electric dysfunction involves a vicious cycle whereby increased cytoplasmic Na release, leads to blunted Ca 2+ signaling to the mitochondria during increased work. [17] [18] [19] [20] Consequently, the failure to stimulate Ca 2+ -dependent dehydrogenases of Krebs cycle [21] [22] [23] [24] [25] results in the net oxidation of the matrix NADH pool. The decreased NADH/ NAD + redox potential, on the one hand, results in a deficiency of reducing equivalents that drive oxidative phosphorylation and ATP production and, on the other hand, compromises the ability to scavenge ROS, owing to the interdependence of the NADH and NADPH redox pools 20 (see schema in Online Figure I ). Mitochondrial NADPH is crucial because it provides the reducing power to maintain the reduced glutathione, thioredoxin, and glutaredoxin pools, all of which are vital for ROS scavenging and the prevention of protein thiol oxidative damage. accumulation during increased work, net oxidation of NAD(P) H, and a massive increase of intracellular ROS, 31 ultimately resulting in abnormal Ca 2+ regulation and arrhythmias. 30 The adverse effects of high [Na + ] c are abolished by CGP-37157 (CGP), an inhibitor of mNCE. 19, 30, 31 In the present study, we examine whether in vivo treatment with CGP prevents the development of HF and SCD using a novel guinea pig model of HF induced by left ventricular (LV) pressure overload combined with a daily β-adrenergic challenge. We show that partial inhibition of mNCE attenuates cardiac remodeling, preserves cardiac contractile function, and protects against HF-associated arrhythmias and SCD, significantly improving overall survival. The results highlight mNCE as a novel target for HF treatment.
Methods
A detailed Methods section is available in the Online Data Supplement.
Results

Daily β-Adrenergic Challenge Accelerates the Transition From LV Hypertrophy to HF
A guinea pig HF model was developed by combining ascending aortic constriction (AC) with daily administration of the β-adrenergic agonist, isoproterenol, via intraperitoneal injection (ACi). The rationale was to expose the pressure-overloaded heart to a period of increased work each day to simulate β-adrenergic stress. The isoproterenol dose was chosen so that it would have minimal effects on cardiac hypertrophic remodeling in the absence of AC. There was no evidence of cardiac hypertrophic remodeling in sham-operated animals exposed to the 4-week isoproterenol challenge (SHAMi) as compared with the shamoperated, untreated group (SHAM). However, in the presence of AC, the same isoproterenol treatment significantly exacerbated the decline in cardiac fractional shortening (FS) evoked by AC alone (Online Figure II) . In ACi, FS decreased from 46.5±1.0% at week 0 (prebanding) to 30.5±1.5% at week 4, whereas with AC alone, FS was not significantly decreased by week 4 (44.2±1.0% at week 0 versus 43.4±2.2% at week 4). Significant cardiac dysfunction in the AC group was observed only after 6 weeks of pressure overload (FS, 38.4±1.2%), whereas at week 8, FS decreased to 29.3±3.3%, which was similar to the functional decline evident at week 4 in ACi (Online Figure II) . Thus, the major effect of the daily isoproterenol challenge was to accelerate the transition from LV hypertrophy to decompensated HF. Figure 1A ). On stimulation (0.1 Hz), [Ca] 2+ m increased abruptly followed by decay during diastole. An increase of work from 0.1 to 1 Hz stimulation resulted in a further increase in MityCam signal (1-F/F0; Figure 1A ). Measurement of peak MityCam signal indicated that accumulation of [Ca] 2+ m during increased work was significantly less in myocytes from ACi hearts than SHAMi hearts, whereas 1 μmol/L CGP treatment fully restored [Ca] 2+ m in ACi myocytes ( Figure 1A and 1B). Isolated cardiomyocytes were challenged with a rapid increase in work from the resting state to 4 Hz stimulation in the presence of 100 nmol/L isoproterenol. NAD(P)H autofluorescence was strongly oxidized during 4 Hz stimulation in ACi cardiomyocytes ( Figure 1C ). NAD(P)H decreased from 67±4.4% at rest to 33±5.7% at the end of the stimulation period, whereas in SHAMi myocytes subjected to the same protocol, NAD(P)H levels were well maintained (67±5.1% at prestimulation versus 66±4.8% at the end of stimulation). Notably, the oxidation of NAD(P)H in ACi myocytes was prevented by treatment with 1 μmol/L CGP (68±5.5% at prestimulation versus 64±9.1% at the end of stimulation; Figure 1C) . CGP had no effect on sarcolemmal Na + /Ca 2+ exchange current at concentrations ≤10 μmol/L (Online Figure IVA) , confirming its specificity for mNCE.
Inhibition of mNCE
The oxidation of the NAD(P)H pool during increased work in ACi cells was associated with increased oxidative stress. ROS accumulation was monitored with the H 2 O 2 -sensitive fluorescent probe 5-(and -6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate (CM-DCF). CM-DCF oxidation rate in SHAMi myocytes was low, with no significant change induced by the increased work ( Figure 1D ). In contrast, Figure 1D ). During stimulation, the CM-DCF oxidation rate in ACi cells was ≈10-fold higher than that in SHAMi cells. The enhanced intracellular ROS accumulation rate in ACi cells was abolished by CGP treatment ( Figure 1D ).
ROS accumulation in ACi cells was markedly increased on stimulation (
Effects of Chronic CGP Treatment on ACi-Induced Cardiac Remodeling and Functional Deterioration
Significant cardiac hypertrophy, pulmonary congestion, and interstitial fibrosis were present in the ACi group by the end of week 4. Heart weight/tibia length was 53% higher in ACi (0.75±0.04 g/cm) versus SHAM (0.49±0.02 g/cm) and lung weight/tibia length was 66% higher in ACi (5.69±0.43 g/cm) versus SHAM (3.41±0.08 g/cm; Figure 2A ). Histological analysis showed that interstitial fibrosis in ACi hearts was 12.5-fold higher than in SHAM ( Figure 2B ). Isoproterenol challenge in the absence of pressure overload did not significantly increase fibrosis, although there was a trend toward more fibrosis in the SHAMi group relative to the SHAM controls (percent fibrotic tissue area was 0.53±0.2 in SHAM versus 1.1±0.5 in SHAMi; P=0.052) after 4 weeks of injections ( Figure 2B ). CGP treatment protected against HF-associated cardiac remodeling: the ACi plus CGP group developed less cardiac hypertrophy (heart weight/tibia length, 0.64±0.04 g/ cm; P<0.05) and pulmonary congestion (lung weight/tibia length, 4.04±0.22 g/cm; P<0.001) at 4 weeks compared with the ACi group ( Figure 2A ). CGP treatment also attenuated interstitial fibrosis, which was decreased by 50% in ACi plus CGP group compared with that in ACi group ( Figure 2B ).
Pressure overload with daily β-adrenergic challenge induced LV hypertrophy and progressive cardiac dilation and impaired contractility within 4 weeks of surgery ( Figure 2C ). Compared with SHAM, FS in the ACi group decreased by 36% (28.9±1.6% in ACi versus 44.9±0.9% in SHAM; P<0.001), and diastolic LV internal dimension increased by 51% (1.07±0.04 cm in ACi versus 0.71±0.01 cm in SHAM; Figure 2 . The effects of CGP-37157 (CGP) treatment on hypertrophic remodeling and cardiac function. A, Heart weight (HW; left) and lung weight (LW; right) were measured at 4 wk after surgery and normalized to tibia length (TL). Isoproterenol challenge had no effects on either HW/TL or LW/TL in sham-operated animals (SHAMi vs SHAM). Pressure overload with daily isoproterenol challenge (ACi) induced cardiac hypertrophy and lung congestion, and CGP treatment attenuated both cardiac hypertrophy and lung congestion (ACi plus CGP). B, Interstitial fibrosis was analyzed with Masson trichrome staining. Representative images from each experimental group (left); measurements of interstitial fibrous tissue (right) showing that pressure overload, together with isoproterenol challenge, induced significant fibrosis in ACi group, which was attenuated by CGP treatment (ACi plus CGP). C, Cardiac function is preserved by CGP. Representative images of echocardiographic study (top); bottom: measurements of fractional shortening (FS; left) and diastolic left ventricular internal dimension (LVIDd; right) showing reduced FS and LV dilation in ACi group but not in CGP-treated group. D, Representative LV pressure-volume loops (left). Heart from ACi group shows increased end-diastolic volume and depressed end-systolic pressure-volume relation. Right: Summary data of end-systolic LV pressure (top) and dP/dt_ip (dP/dt normalized to pressure; bottom). Isoproterenol treatment in the absence of aortic constriction (SHAMi) had no effect on cardiac function. June 20, 2014 P<0.001; Figure 2C ). Contractile impairment was also confirmed by in vivo hemodynamic studies: +dP/dt normalized to pressure (+dP/dt_ip) in the ACi group decreased by 32% compared with that of SHAM controls (73.5±4.0 in SHAM versus 49.9±2.1 in ACi; P<0.001; Figure 2D ). In contrast, animals treated with CGP displayed well-maintained cardiac function without LV dilation. No significant differences in FS, LV internal dimension, or +dP/dt_ip between the SHAM and ACi plus CGP groups were observed. β-Adrenergic treatment alone (SHAMi versus SHAM) had no effect on cardiac hemodynamic parameters.
Effects of β-Adrenergic Challenge, Pressure Overload, and CGP on Heart Rate
Heart rate (HR) responses to the daily isoproterenol injection were recorded in a subset (3-6 guinea pigs) of animals from each experimental group by means of implanted biopotential telemetric transmitters. Baseline and maximal HR, determined by analysis of ECG acquired during and after isoproterenol injections, were compared at 1 and 4 weeks postsurgery (Online Figure V) . Baseline HR was unaffected by chronic β-adrenergic treatment in the absence of pressure overload (SHAMi versus SHAM); however, the ACi group had higher baseline HR at weeks 1 and 4 after pressure overload compared with SHAMi controls (Online Figure V) . Chronic treatment with CGP (ACi plus CGP), administered continuously at a dose of 0.015 mg/kg per hour by means of an implanted osmotic pump, attenuated but did not completely eliminate the increase of baseline HR at week 1 but abolished it at week 4 (baseline HR at week 4: 218.8±9.0 beats per minute in SHAMi versus 206.2±7.5 beats per minute in ACi plus CGP). After injection of isoproterenol, HR rapidly increased to a maximum of ≈390 to 400 beats per minute in all groups and then slowly declined back to the baseline rate in 4 to 5 hours (Online Figure V) . The peaks and kinetics of the normalized chronotropic response to isoproterenol were not significantly different between the experimental groups. 
Antiarrhythmic Effects of CGP
Telemetry studies revealed that animals in the ACi HF group had a high incidence of premature ventricular beats (PVBs; Figure 3 ). PVB frequency was significantly decreased by CGP treatment. To evaluate the antiarrhythmic effects of CGP, PVBs were counted in a 2-hour period at baseline and a 4-hour period after isoproterenol injection at weeks 1 ( Figure 3A ) and 4 ( Figure 3B ) after surgery. At baseline, occasional PVBs were detected in all groups, but the incidence of PVB was low in SHAM and SHAMi groups. Moreover, the rates did not change from week 1 to week 4 (week 1, 3.3±2.0 counts per hour; week 4, 4.0±2.5 counts per hour). In contrast, at baseline, the ACi group had a much higher incidence of PVB (23.5±5.3 counts per hour in week 1) and the frequency increased as HF developed (51.3±10.1 counts per hour in week 4). CGP treatment significantly reduced the baseline frequency of PVB as compared with ACi (ACi plus CGP PVB frequency: 9.2±6.3 counts per hour in week 1 and 13.0±3.7 counts per hour in week 4). Isoproterenol increased PVB frequency in all groups. At week 1, PVB frequency in SHAMi after isoproterenol (1 mg/kg) was 104.0±36.2 counts per hour, whereas in ACi, PVB frequency increased to 388.4±35.1 counts per hour after isoproterenol injection ( Figure 3A and 3B, right panels). CGP treatment inhibited the arrhythmogenic effect of the β-adrenergic challenge: PVB frequency after isoproterenol injection in the ACi plus CGP group was 219.8±31.2 counts per hour, a decrease of 43% compared with the ACi group. Although, as mentioned above, the HR response to isoproterenol was similar in all of the groups, the increase in PVB frequency after the injection was much less in week 4 than in week 1 (30.6±8.1 counts per hour in SHAMi, 105.9±12.5 counts per hour in ACi, and 32.5±8.0 counts per hour in ACi plus CGP; Figure 3A and 3B, right panels), despite the isoproterenol dose being higher (2 mg/kg). Increased intrinsic sympathetic drive related to postoperative stress in week 1 or β-adrenergic receptor desensitization in week 4 might explain this difference.
The antiarrhythmic effect of CGP was greater in week 4, both at baseline and after isoproterenol injection ( Figure 3A and 3B). CGP treatment (comparing ACi plus CGP with ACi) suppressed baseline PVB frequency by 60% in week 1 and 75% in week 4. In the context of acute isoproterenol injection, CGP decreased PVB frequency by 43% in week 1 and 67% in week 4. Analysis of ECG data revealed prolonged QT intervals (QTc is corrected for HR) in both ACi and ACi plus CGP groups ( Figure 3C ). There was no difference in QTc between ACi and ACi plus CGP groups at either week 1 or week 4, indicating that CGP treatment did not reverse QT prolongation in the HF model ( Figure 3C ; right panel). QTc was also unaffected by the daily β-adrenergic challenge; there was no difference in QTc interval between SHAM and SHAMi groups.
Prevention of HF-Associated SCD by CGP and Overall Mortality Benefit
The ACi model was associated with a remarkably high incidence of SCD. Here 61.3% of ACi animals died by the end of 4 weeks (Figure 4 ) without overt HF symptoms (eg, cyanosis, labored breathing, inactivity, piloerection, or cachexia). ECG analysis showed that death was preceded by sustained polymorphic ventricular tachycardia or fibrillation (VT/VF; Figure 3A and 3B, left panels). Interestingly, SCD did not occur during the peak of the HR response after isoproterenol injection, but usually happened several hours after the injection (5/6 SCD events occurred between 2 and 5 hours postinjection, 1 occurred 9 hours postinjection), when the HR had recovered almost to baseline. CGP treatment (ACi plus CGP) significantly reduced the 4-week death rate to just 14.3%, which was not significantly different from that of the SHAMi control (Figure 4) . Moreover, all of the deaths in CGP-treated group and in the SHAMi group occurred in the first week after surgery, perhaps attributable to the postoperative stress making the animals more susceptible to arrhythmias. Survival analysis of the ACi group indicated that the death rate was higher in week 1 (22.4%) and week 4 (26.9%) compared with that in week 2 (15.8%) and week 3 (18.8%). Similar to the other groups, the higher death rate in week 1 in ACi may reflect the overall effects of postoperative stress, along with a higher susceptibility to isoproterenol-induced arrhythmias. Considering that the PVB frequency after isoproterenol injection in week 4 is only 27% of that in week 1, the higher death rate (26.9%) in week 4 suggests that PVBs may be more life-threatening because of HF-associated changes in the arrhythmogenic substrate.
Antiarrhythmic Effects of CGP on the Isolated Failing Heart
We next determined whether arrhythmia susceptibility and cardiac function in ACi failing hearts could be rescued by acute treatment with 1 μmol/L CGP in isolated perfused hearts. Langendorff-perfused SHAMi and ACi hearts, isolated at week 4, were challenged with 10 μmol/L isoproterenol for 15 minutes. Cardiac contractility and ECG were analyzed before, during, and after isoproterenol challenge. Baseline contractility before isoproterenol was significantly reduced in ACi hearts ( Figure 5A) ; LV diastolic pressure, +dP/dt, and -dP/dt of ACi hearts were only 37%, 38%, and 36%, respectively, of values in SHAMi hearts ( Table 1) . Administration of isoproterenol increased cardiac contractility by a similar percentage in both ACi and SHAMi groups. However, ACi hearts were more sensitive to the stress of isoproterenol challenge; contractility of ACi hearts was depressed more after isoproterenol washout. In the postisoproterenol state, LV diastolic pressure, +dP/dt, and -dP/dt of ACi hearts were 12%, 16%, and 16% of values in SHAMi hearts (Table 1) . Treatment with CGP had no statistically significant effects on cardiac contractility during preisoproterenol or isoproterenol states, but attenuated contractile dysfunction after isoproterenol treatment (Table 1) . Treatment with CGP improved LV diastolic pressure, +dP/dt, and -dP/dt recovery in the postisoproterenol state by 205%, 135%, and 120%, as compared with ACi hearts without CGP treatment (Table 1) .
HR variability analysis was applied to quantify changes in the ECG in the SHAMi and ACi hearts under different experimental conditions. Treatment with 10 μmol/L isoproterenol did not induce overt arrhythmias during the period of maximum LVPD in either group. There were no differences in RR interval, standard deviation of RR interval, root mean square of successive difference, short-term dispersion, or long-term dispersion between SHAMi, ACi, and ACi plus CGP treatment groups during preisoproterenol and isoproterenol states (Table 2) . However, after washout of isoproterenol, HR variability of ACi hearts was dramatically increased compared with that of SHAMi hearts (clusters of points are indicative of ectopic activity in the Poincaré plots in Figure 5B ), whereas CGP treatment completely inhibited the arrhythmias in ACi hearts in the postisoproterenol state ( Figure 5B ; Table 2 ). There were no differences in RR interval, standard deviation of RR interval, root mean square of successive difference, short-term dispersion, or long-term dispersion between SHAMi and ACi plus CGP-treated hearts (Table 2 ). 
Discussion
The major findings of the present study were that: (1) the transition from compensated pressure overload hypertrophy to HF is exacerbated by a daily β-adrenergic challenge; (2) SCD is a major contributor to mortality in the ACi HF model; (3) the mNCE inhibitor, CGP, prevents cardiac contractile decompensation, blunts hypertrophic remodeling, decreases arrhythmia incidence, and prevents SCD associated with HF. The present study was motivated by our earlier findings that [Na + ] c overload, by increasing the driving force for mNCEmediated Ca 2+ extrusion from the mitochondrial matrix, results in insufficient [Ca] 2+ m accumulation during increased work. 17, 19, 30 If the Ca 2+ signal to the mitochondria falls below a critical threshold level, 19 Ca
2+
-dependent activation of Krebs cycle enzymes is disrupted, 29 causing the mitochondrial pyridine nucleotide redox potential (NAD(P)H/NAD(P) + ) to become more oxidized. The consequent decrease in reducing equivalents driving oxidative phosphorylation (NADH) and the antioxidant pathways (NADPH) causes both an impairment of energy supply and ROS overload ( Figure 1C and 1D) . This pathological mechanism was demonstrated in normal myocytes overloaded with [Na + ] c , 17 myocytes treated with the Na + /K + inhibitor ouabain, 30 and in myocytes isolated from failing (AC model) guinea pig hearts. 19 In the present study, we demonstrated that the net oxidation of NAD(P)H pool and increased oxidative stress during rapid pacing (4 Hz) in the presence of isoproterenol is also present in the ACi model. The increase in NAD(P)H oxidation, ROS accumulation, and arrhythmias associated with [ Figure 1C and 1D ). The present findings are the first to demonstrate that chronic treatment with CGP prevents the progressive decline in contractile function and SCD in vivo in an animal model of HF. The ACi model was developed to incorporate both hemodynamic stress (LV pressure overload) and chronic sympathetic hyperstimulation, 2 factors that are known to contribute to HF and SCD in humans. 32, 33 Compared with pressure overload alone, the ACi model accelerated the decline in function and pathology of HF, whereas isoproterenol treatment in the absence of pressure overload (SHAMi) had no significant effects on cardiac function and remodeling in control animals.
A unique feature of the ACi model is the high incidence of SCD (≈60% at 4 weeks), which is manifested as an increased death rate even in the first week post-AC, when function is largely preserved, and continues during the course of HF progression. Notably, the ACi model shows QTc prolongation even after only 1 week of pressure overload, before overt contractile dysfunction, as well as a large increase in spontaneous PVBs. The PVB rate and the incidence of VT/VF were both suppressed by CGP treatment; however, the QTc prolongation was not reversed, suggesting that the alterations in sarcolemmal ionic currents during hypertrophy, by themselves, are not sufficient to account for the increased automaticity and tendency toward re-entry underlying SCD. Presumably, the combined effects of ion channel remodeling, oxidative stress, and the change in the myocardial substrate were all involved in setting the stage for VT/VF. In this light, it is still not clear whether long QTc is a useful predictor of SCD in human HF. Breidthardt et al 34 reported prolonged QTc interval (≥440 ms) in 72% of patients with acute destabilized HF, but 720-day all-cause mortality was no different in patients with prolonged versus normal QTc intervals. Patients with prolonged QRS interval, however, had a significant 2-fold increase in mortality. Similarly, QTc was determined to have no independent prognostic value on 1-year mortality in a subset of patients with congestive HF in a recent clinical trial. 35 In general, though, the overall risk of malignant arrhythmias increases with the magnitude of QTc prolongation, 36 and more refined analyses, such as QTc variability, may have predictive value for SCD, 37 perhaps as a better indicator of QT dispersion. 38 The present results suggest that prolonged QTc may provide the substrate for potentially fatal arrhythmias, but that a secondary event-we propose an oxidative stress event secondary to an energy/redox supply and demand mismatchwould be required to initiate SCD. The nonlinear nature of the secondary event could, therefore, account for the unpredictability of SCD.
Apart from genetically engineered animals, 39 the ACi model is, to our knowledge, one of the few animal models of HFassociated acquired long QT that displays a high incidence of spontaneous SCD. The accelerated transition between the compensated and decompensated states should be useful for investigating the mechanisms behind progressive systolic and diastolic dysfunction, as well as vulnerability to arrhythmias, in future studies.
Altered β-adrenergic receptor (β-AR) signaling is known to be a key player in the development of HF. 40, 41 In addition to impairment of the inotropic, chronotropic, and lusitropic effects of β-AR stimulation in HF, chronic hyperactivation of the receptor results in receptor desensitization, detrimental effects on cardiac function, and structural remodeling, which can be mitigated by β-blockade. The impact of selective β-AR signal activation on the heart depends on the dose and duration of β-AR agonist administration. 42 In our study, the chronic effects of isoproterenol on cardiac remodeling were minimized by selecting an isoproterenol dose that had no independent hypertrophic effects in sham-operated animals and by administrating isoproterenol with repeated injections that induced only transient activation of β-AR signaling. The β-AR challenge had detrimental functional effects (arrhythmias and impaired postisoproterenol contractility) on LV pressure-overloaded animals, but not on controls, suggesting that the pressure-overloaded heart is more vulnerable to β-AR activation. This is consistent with other animal studies. For example, in spontaneously hypertensive rats with LV hypertrophy, infusion of isoproterenol initiated a transition from compensated hypertrophy to HF, whereas the same infusion had no significant effects on cardiac function and remodeling in control rats. 43 Genetically modified mouse lines that have constitutively increased β-AR drive with normal cardiac function and structure are also more susceptible to pressure overload. 44, 45 Our finding that CGP treatment protects pressure-overloaded hearts (both in vivo and ex vivo) from the detrimental effects of β-AR challenge supports the hypothesis that blunted [Ca] 2+ m accumulation leading to oxidative stress is a key event underlying increased vulnerability of the failing heart to β-AR-mediated cardiac dysfunction.
In addition to exacerbating contractile dysfunction, β-AR challenge also predisposed the pressure-overloaded heart to VT/VF, and CGP protected ACi animals from both high PVB rate and SCD. Increased sympathetic activity during physical or emotional stress is known to provoke VT/VF in catecholaminergic polymorphic VT, and elevated diastolic Ca 2+ and hyperactive ryanodine receptors are thought to be critical factors leading to SCD in animal models of catecholaminergic polymorphic VT. 46 48 demonstrated that increased SR Ca 2+ by β2-AR activation results in enhanced arrhythmogenesis in myocytes from human and rabbit failing hearts. Interestingly, in the ACi model, the proarrhythmic effect of β-AR challenge was not evident during the peak of the response, but was revealed only after recovery from the increased work. We propose that CGP is protecting against damage induced by mitochondrial ROS accumulation by preserving the pyridine nucleotide/antioxidant capacity during β-AR activation. Among the potential ROS targets, the local oxidation of the ryanodine receptors by mitochondrial ROS 49 could underlie spontaneous Ca 2+ release and ectopic activity. Ryanodine receptor channels have multiple cysteine residues that sense the local redox state, and their oxidation is responsible for increased spontaneous SR Ca 2+ leak in HF, which can be normalized by dithiothreitol. 13 In this light, we have previously demonstrated that CGP, by increasing the [Ca] 2+ m response and preserving NAD(P)H redox potential during increased work, can prevent delayed afterdepolarizations triggered by ouabain-induced Na + overload in myocytes, hearts, and intact animals. 30 This mechanism is the likely explanation for the CGP-mediated protection against postisoproterenol ectopic activity observed in the isolated perfused ACi hearts ( Figure 5 ).
In addition to ROS-driven dysfunction, impaired mitochondrial energetics in HF also contribute to cardiac decompensation. 50 For example, limitations of ATP delivery could impair diastolic function by affecting the Ca 2+ removal capacity via SR Ca 2+ ATPase when energy demand increases during β-AR stimulation. This has been observed in studies of energetically deficient animal models. In the creatine kinase-deficient mouse, the reduced energy reserve leads to a decreased capacity of SR Ca 2+ ATPase to remove cytosolic Ca 2+ . 51, 52 A peroxisome proliferator-activated receptor γ coactivator 1-β-knockout mouse also displays reduced respiration rate and ATP production 53 ; these animals showed increased susceptibility to catecholamine-induced arrhythmias. 54 Cardiomyocytes from these mice have normal Ca 2+ transients at rest, but elevated [Ca] 2+ c and spontaneous diastolic Ca 2+ transients were induced after isoproterenol administration. 54 By improving energy supply, CGP treatment could thus help to maintain the activity of SR Ca 2+ ATPase or other energy-dependent processes during increased work to preserve systolic and diastolic function.
The present findings highlight the central role of oxidative stress in both the functional deterioration and arrhythmias associated with HF progression. In addition to direct damage to the myocyte, mounting evidence indicates that ROS modulate various signaling pathways involved in hypertrophic growth, apoptotic and necrotic cell death, and proliferation of cardiac fibroblasts. 11, 55, 56 ROS are also downstream mediators of neurohumoral stimuli implicated in HF, such as angiotensin II, endothelin 1, and tumor necrosis factor α. Increased ROS can also directly activate signaling cascades including tyrosine kinases, mitogen-activated protein kinases, protein kinase C, and phosphoinositide 3-kinase, 57 which are potent regulators of cardiac growth. The effects of CGP on these downstream effectors of ROS signaling remain to be determined, but could also contribute to the observed protection. Nevertheless, given that the hypertrophic response was only partially decreased by CGP treatment, the major beneficial effect of CGP may be to prevent the redox modification of proteins (eg, ion channels, myofilament proteins, and mitochondrial enzymes) that lead to contractile dysfunction and deficient energetics. Recent studies confirm the pre-eminent role of mitochondrial ROS in HF; for example, a mitochondrially targeted antioxidant peptide (SS-31) protects animals from angiotensin II-induced cardiac hypertrophy and fibrosis, 14 and overexpression of mitochondrial, but not cytosolic, catalase prevents changes in the proteome of mice subjected to pressure overload-induced HF. 15 CGP treatment intervenes in the mechanism leading to the mitochondrial ROS overload while preserving energy supply and demand balance, which may have advantages compared with strategies that simply attempt to increase the ROS scavenger capacity.
In summary, CGP preserves cardiac function, attenuates remodeling and fibrosis, and prevents SCD in the guinea pig HF and SCD model produced by pressure overload combined with β-AR stimulation. The beneficial effects of CGP can be attributed to the effects of restored [Ca] 2+ m dynamics by CGP on mitochondrial energetics and redox balance. Additional studies will be needed to characterize all of the HF-associated modifications affected by CGP treatment, including cellular redox status, ROS balance, the electrophysiology of the heart, excitation-contraction coupling, energy metabolism, and post-translational protein modifications. More work will also be required to determine whether CGP treatment can reverse established LV hypertrophic remodeling to prevent decompensation and SCD in this model. In addition, given the known variations in [Na + ] c in different species, 58 the efficacy of CGP may be different in other models of HF and in humans. Nevertheless, the findings support the hypothesis that [Ca] 2+ m dynamics plays a critical role in the development of HF and HF-associated SCD and implicate mNCE as a novel therapeutic target for HF.
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